Clinical Trial

Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy

Study acronym: NeuroLight
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-01-06; most recent amendment 2024-03-05.
Status change: Recruiting → Active, Not Recruiting 2023-09-28
Status change: Not Yet Recruiting → Recruiting 2022-02-23
Trial Details
NCT Number NCT05199389
Lead Sponsor Jessa Hospital
Conditions Chemotherapy-induced Peripheral Neuropathy
Enrollment 60 participants
Start Date 2022-01-31
Primary Completion 2023-11-15 (estimated)
Study Completion 2028-11-10 (estimated)
Updated on ClinicalTrials.gov 2024-03-06